vialroom

#dosing-titration 2026-04-10

Friday16 messages4 participantstimes are UTC
Highlights from this day
  • mid_week_mo — unrelated but the argument for splitting is a flatter curve. the argument against is you have doubled your injections for a guess 17:12
  • gorse_gains — if the current dose is still working, going up is spending headroom you might want later 19:19
  • mg_per_ml — i drifted from sunday to wednesday over a year and only noticed when i checked the log, ask me again in a month 20:07
  • mg_per_ml — i jumped a rung once to catch up after a supply gap and it was a bad week. would not repeat 20:27
GG

update from 8 months ago: held at the same dose the whole time and still losing slowly

MW

unrelated but the argument for splitting is a flatter curve. the argument against is you have doubled your injections for a guess

👍5
GG

thats normal

fridge-temps.csv
940 rows · not retained in the public archive
⚠️1📈11

i went from 0.5 to 2.5 and honestly could not tell the difference in appetite

follow up if it "stopped working after four days" that is almost never pharmacokinetics

the ladder in the trials is a starting point, not a schedule you owe anyone

TT

whats your rule for when a side effect means hold rather than push

GG

anyone tracked whether a smaller more frequent dose changed their side effects

if the current dose is still working, going up is spending headroom you might want later

TT

plateau versus set point is not answerable in under six months of data

MP

i drifted from sunday to wednesday over a year and only noticed when i checked the log, ask me again in a month

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
MP

i jumped a rung once to catch up after a supply gap and it was a bad week. would not repeat

👀1💀15😂1

steady state is 5 weeks